Vasorum gets FDA green light for its vascular closure device aimed at arterial punctures

Irish devicemaker Vasorum got FDA approval for its Celt ADC vascular closure device that is aimed at arterial puncture closure.

The device is indicated for both diagnostic and anticoagulated percutaneous interventional cardiology and radiology patients. A study of 207 interventional cardiology procedure patients that was conducted in four cardiology centers in the U.S. in Europe helped support the approval, the company said.

"With more than 20,000 patient implants to date in Europe, Celt ACD has proven itself to be a best in class arterial puncture closure device,”  Dr. James Coleman, co-founder and CEO of Vasorum, said in a statement. He added that the device “allows immediate closure of multiple re-sticks in calcified vessels and is also very comfortable for patients.”


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

More than 8 million catheter procedures are performed annually, which pegs the femoral artery closure device market at about $8 billion, the company estimated.

The number of procedures is expected to surpass 10 million in the next four years. On top of the number of interventional cardiology procedures, growth is also being fueled by more peripheral vascular, neuro-vascular and other catheter procedures that require more patient friendly devices and more efficient patient discharge from hospitals.

Cardiva Medical and Cardinal Health are also is a players in the vascular closure device arena.

-here’s the release

Read more:
Cardinal Health will snatch up Accessclosure for $320M
Vascular closure player Cardiva gets $12.5M, J&J exec to commercialize
Covidien plans to slash 183 jobs in NY plant closure

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.